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ABSTRACT
Background: Rebamipide, a gastroprotective drug, has been reported to suppress gastric mucosal inflamma-
tion. In Japan, rebamipide eyedrops have recently been approved for the treatment of dry eye disease. Some
patients with allergic conjunctival diseases such as vernal keratoconjunctivitis (VKC) or atopic keratoconjunc-
tivitis (AKC) manifest dry eye with decreased tear break-up time only. We report patients with VKCAKC refrac-
tory to anti-allergic treatments who responded to the combination of rebamipide eyedrops and conventional
anti-allergic treatments with anti-allergic- andor immunosuppressivesteroid eyedrops.
Methods: Four patients with allergic conjunctival diseases with giant papillae (VKC or AKC) instilled re-
bamipide eyedrops three or four times a day for varying periods. All had dry eye with decreased tear break-up
time. We evaluated changes in the size of their giant papillae using Image J software.
Results: We observed attenuation of the giant papillae in all 4 patients. In 2 patients with severe disease,
whose giant papillae had become larger despite the administration of tacrolimus and steroids, the addition of
rebamipide contributed to their attenuation. In 2 patients with mild disease, the giant papillae had become
larger or remained the same size despite the administration of anti-allergy drugs; the addition of rebamipide
eyedrops also resulted in the attenuation of their giant papillae.
Conclusions: Our findings suggest that rebamipide eyedrops might attenuate giant papillae in patients with
allergic conjunctival diseases and that these eyedrops may be useful for the treatment of not only dry eye but
also of allergic conjunctival diseases.
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INTRODUCTION
Rebamipide eyedrops have been approved in Japan
for the treatment of dry eye disease. They up-regulate
the production and secretion of mucin.1 Kinoshita et
al.2,3 reported that the administration of 2% re-
bamipide was well-tolerated and effectively improved
objective signs and the subjective symptoms of dry
eye.
Rebamipide, a gastroprotective drug, increases
gastric mucus production4,5 and suppresses gastric
mucosal inflammation6,7 Naito et al.8 reported that re-
bamipide was dominantly distributed in mucosal tis-
sues. Elsewhere we showed that it suppressed polyI:
C-induced inflammatory cytokines in human conjunc-
tival epithelial cells9 and Kimura et al.10 documented
that rebamipide protects corneal epithelial cells from
the TNFα-induced disruption of barrier function by
maintaining the distribution and expression of ZO-1
as well as the organization of the actin cytoskeleton.
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Fig.　1　We measured the size of the giant papillae on pho-
tographs of the ocular surface obtained before and at the in-
dicated times during rebamipide treatment using Image J 
software.
It also suppressed the TNFα-induced expression of
interleukin-6 and interleukin-8 at the mRNA- and pro-
tein level and inhibited the TNFα-induced degrada-
tion of IκBα.11 Some patients with allergic conjuncti-
val diseases manifest dry eye with only decreased
tear break-up time (BUT).12,13
We prescribed rebamipide eyedrops to patients
with allergic conjunctival diseases with giant papillae
who presented with dry eye. We now report patients
with VKCAKC refractory to conventional treatment
with anti-allergic- andor immunosuppressivesteroid
eyedrops who responded to the combination of re-
bamipide eyedrops and conventional anti-allergic
treatments.
METHODS
This study was a case report on the VKCAKC pa-
tients with giant papillae intractable for a conven-
tional anti-allergic treatment undergoing topical com-
bined therapy using rebamipide eyedrops. Our study
included 4 patients with allergic conjunctival diseases
with giant papillae (VKC or AKC) and dry eye with
decreased tear break-up time, which we treated with
rebamipide in 2012. They were 3 males and 1 fe-
males; their age ranged from 10 - 48 years (mean
29.5). They were instructed to instill rebamipide eye-
drops three or four times a day for varying periods.
We started the administration of rebamipide eye-
drops when the patients have dry eyes, and the size
of giant papillae had increased despite the more than
2-week administration of tacrolimus and steroids (se-
vere cases), or had become larger or remained the
same despite the use of anti-allergy drugs (mild
cases). We observed attenuation of the giant papillae
in all 4 patients with VKC or AKC. We evalutated
changes in the size of their giant papillae and in the
area of involvement. The study protocol was ap-
proved by the ethical review board of Kyoto Prefec-
tural University of Medicine; all patients provided
written informed consent.
We marked the papillae on photographs of the ocu-
lar surface and calculated their size using Image J
software (Fig. 1). We show their total- and average
size. Data were expressed as the mean ± SE and
evaluated by Student’s t-test using Microsoft Excel
software.
RESULTS
CASE 1
47-year-old man with left AKC. He previously had un-
dergone penetrating keratoplasty for limbal stem cell
deficiency. He was on topical tacrolimus (0.1%, 2
day), fluorometholone (0.1％day), and systemic
prednisolone (10 mgday) for more than a year be-
fore starting therapy with rebamipide eyedrops. We
prescribed rebamipide eyedrops to him when the size
of his giant papillae and the area of involvement con-
tinued to increase; his left BUT was 0 sec at that time.
Two weeks of rebamipide treatment yielded no at-
tenuation although the discharge and itching were re-
duced. After 6 weeks the giant papillae were smaller
and his subjective symptoms were milder and the
prednisolone dose was reduced to 5 mgday. After 13
weeks of rebamipide therapy his papillae were almost
flat. Prednisolone was stopped 17 weeks after the
start of rebamipide administration and at the last
follow-up, performed about one year later, his giant
papillae were silent (data not shown). Figure 2 shows
the pictures of his left upper eyelid, drug history and
graphs showing the size of total- and the each area of
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Fig.　2　Case 1 - A patient with atopic keratoconjunctivitis. The size of total- and each area 
of the giant papillae at 0-, 2-, and 6 weeks after starting rebamipide treatment are shown. 
Data are expressed as the mean ± SE and evaluated by Student’s t-test using Microsoft 
Excel software (*p < 0.05).
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the giant papillae at 0-, 2-, and 6 weeks after starting
rebamipide treatment.
CASE 2
13-year-old boy with right VKC. The topical admini-
stration of tacrolimus (0.1%, 2day) and betametha-
sone (0.1%, 4day) had been ineffective and he suf-
fered severe VKC with massive superficial punctate
keratopath and visual impairment. Therefore, we
added systemically prednisolone (10 mgday) for 3
weeks and then replaced betamethasone with
fluorometholone (0.1%, 4day for 3 weeks). However,
despite these treatments his VKC again became se-
vere and rebamipide therapy was started; his right
BUT was 2 sec at that time. After 3 weeks his giant
papillae were smaller and the severity of his symp-
toms was decreased. After 6 weeks the giant papillae
were almost flat; their flattening continued until week
Ueta M et al.
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Fig.　3　Case 2 - A patient with vernal conjunctivitis. The size of total- and each area of 
the giant papillae at 0-, 3-, and 6 weeks after starting rebamipide treatment are shown. 
Data are expressed as the mean ± SE and evaluated by Student’s t-test using Microsoft 
Excel software (***p < 0.005).
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14. Figure 3 shows the pictures of his left upper eye-
lid, drug history and graphs showing the size of total-
and the each area of the giant papillae at 0-, 3-, and 6
weeks after the start of rebamipide instillation.
CASE 3
When we first saw this 10-year-old girl with VKC she
was on topical fluorometholone (0.1%, 4day) and olo-
patadine (0.1%, 4day). We added rebamipide eye-
drops (4day); her right BUT was 2 sec at that time.
Although she arbitrarily stopped fluorometholone in-
stillation after one week, after 2 weeks of rebamipide
treatment her giant papillae became smaller and the
severity of discharge and itching was lessened. After
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Fig.　4　Case 3 - A patient with vernal conjunctivitis. The size of total- and each area 
of the giant papillae at 0-, 2-, and 4 weeks after starting rebamipide treatment are 
shown. Data are expressed as the mean ± SE and evaluated by Student’s t-test using 
Microsoft Excel software (**p < 0.01).
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4 weeks her giant papillae were yet smaller and flat-
ter. She subsequently was treated elsewhere. Figure
4 shows the pictures of his left upper eyelid, drug his-
tory and graphs showing the size of total- and the
each area of her giant papillae at 0-, 2-, and 4 weeks
after the start of rebamipide therapy.
CASE 4
This 48-year-old man presented with bilateral AKC.
He had suffered several episodes of herpetic keratitis
in the right or left eye. He was treated with olopata-
dine (0.1%, 4day) without topical steroids to prevent
the recurrence of herpetic keratitis. Rebamipide treat-
ment was added when his giant papillae became big-
ger and the area of involvement increased; his right
and left BUT was 2 sec at that time. After 6 weeks his
discharge and itching were reduced and his giant pa-
pillae were smaller as was the area of involvement.
Figure 5 shows the pictures of his both upper eyelid,
drug history and graphs showing the size of total- and
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Fig.　5　Case 4 - A patient with atopic keratoconjunctivitis. The size of total- and each 
area of the giant papillae at 0- and 6 weeks after starting rebamipide treatment are shown. 
Data are expressed as the mean ± SE and evaluated by Student’s t-test using Microsoft 
Excel software (**p < 0.01).
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the each area of the giant papillae at 0- and 6 weeks
after the start of rebamipide treatment.
DISCUSSION
Our findings suggest that rebamipide eyedrops might
contribute to the reduction of giant papillae in pa-
tients with AKC and VKC.
Rebamipide has been used to treat gastritis and
gastric ulcers; it suppresses gastric mucosal inflam-
mation4,5 and increases gastric mucus production.2,3
We posited that rebamipide eyedrops may also exert
anti-inflammatory effects on the ocular surface. Else-
where we reported that rebamipide suppressed the
polyI: C-induced production of CXCL10, CXCL11,
RANTES, MCP-1, and IL-6 in human conjunctival epi-
thelial cells, and that its topical administration sup-
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pressed conjunctival allergic eosinophil infiltration in
our murine allergic conjunctivitis model.6 Others
found that rebamipide protects corneal epithelial cells
from the TNFα-induced disruption of barrier func-
tion11 and that it suppressed the TNFα-induced ex-
pression of interleukin-6 and interleukin-8 at the
mRNA- and protein level.7
We administered rebamipide eyedrops to 4 pa-
tients with allergic conjunctival diseases with giant
papillae and found that it helped to decrease their
size and area of involvement. In two patients (cases 1
and 2) whose giant papillae worsened despite the ad-
ministration of immunosuppressants and steroids,
the addition of rebamipide eye drops exerted anti-
inflammatory effects. In the other patients with less
severe disease (cases 3 and 4), the administration of
rebamipide eyedrops with anti-allergy drugs also pro-
duced anti-inflammatory effects. Based on our obser-
vations we suggest that the anti-inflammatory effects
of rebamipide eyedrops may help to combat human
ocular surface inflammation.
On the other hand, in a patient with giant papillary
conjunctivitis induced by soft contact lenses, the ad-
ministration of rebamipide eyedrops failed to reduce
the size of the giant papillae (data not shown). There-
fore, we think that rebamipide might not be effective
in patients with giant papillary conjunctivitis.
On the other hand, we also encountered a patient
whose giant papillae became smaller and the dis-
charge and itching were alleviated by the sole treat-
ment with rebamipide eyedrops (Supplementary Fig.
1). This suggests that even the sole administration of
rebamipide eyedrops may reduce mild giant papillae.
To confirm the effectiveness of rebamipide eyedrops
in the treatment of various allergic conjunctival dis-
eases, more investigations are needed.
In conclusion, our experience suggests that the
combination of rebamipide eyedrops and conven-
tional anti-allergic treatments with anti-allergic- and
or immunosuppressivesteroid eyedrops may repre-
sent a new effective therapy for VKCAKC refractory
to the usual anti-allergic treatments and that re-
bamipide eyedrops-may also be effective in the treat-
ment of not only dry eye but also allergic conjunctival
diseases.
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